- Home
- PNI vs EYEN Comparison
PNI vs EYEN Comparison
Compare PNI & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- EYEN
- Stock Information
- Founded
- PNI 2002
- EYEN 2014
- Country
- PNI United States
- EYEN United States
- Employees
- PNI N/A
- EYEN N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- EYEN Health Care
- Exchange
- PNI Nasdaq
- EYEN Nasdaq
- Market Cap
- PNI 75.2M
- EYEN 2.9M
- IPO Year
- PNI N/A
- EYEN 2018
- Fundamental
- Price
- PNI $6.69
- EYEN $10.22
- Analyst Decision
- PNI
- EYEN Hold
- Analyst Count
- PNI 0
- EYEN 4
- Target Price
- PNI N/A
- EYEN $2.00
- AVG Volume (30 Days)
- PNI 26.4K
- EYEN 10.0M
- Earning Date
- PNI 01-01-0001
- EYEN 08-11-2025
- Dividend Yield
- PNI 4.76%
- EYEN N/A
- EPS Growth
- PNI N/A
- EYEN N/A
- EPS
- PNI N/A
- EYEN N/A
- Revenue
- PNI N/A
- EYEN $67,063.00
- Revenue This Year
- PNI N/A
- EYEN $7,680.45
- Revenue Next Year
- PNI N/A
- EYEN $315.38
- P/E Ratio
- PNI N/A
- EYEN N/A
- Revenue Growth
- PNI N/A
- EYEN 663.82
- 52 Week Low
- PNI $6.03
- EYEN $0.85
- 52 Week High
- PNI $7.89
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- PNI 47.83
- EYEN 69.20
- Support Level
- PNI $6.61
- EYEN $3.68
- Resistance Level
- PNI $6.71
- EYEN $11.40
- Average True Range (ATR)
- PNI 0.07
- EYEN 2.03
- MACD
- PNI 0.01
- EYEN 0.58
- Stochastic Oscillator
- PNI 61.54
- EYEN 73.25
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.